The first 350 patients have currently been enrolled the A.D.O.P.T. (Autonomous Blood Drawing Optimization and Performance Testing) Trial at study site Result Laboratorium in the Albert Schweitzer ...
Dr. Fred Moll and Vitestro CEO Toon Overbeeke Sonder Capital co-led the $22 million investment in Vitestro to ramp up production and commercialization. UTRECHT, The Netherlands, April 30, 2024 (GLOBE ...
Labcorp Venture Fund, Mayo Clinic, Sutter Health, InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht invest alongside existing investors Invest-NL, EIC Fund, Fred Moll, NYBC Ventures, and ...
Vitestro has raised $70m to advance development and broaden the commercialisation of its autonomous blood-drawing robot. The Dutch company's oversubscribed Series B financing round saw a mix of ...
UTRECHT, Netherlands, Aug. 28, 2024 /PRNewswire/ -- Vitestro, a pioneer in the field of medical robotics, is proud to announce that its innovative automated blood drawing device has received CE ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The FDA has authorized Vitestro's Aletta system, the first standalone robotic device for ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. This week’s edition of InnovationRx looks at Vitestro’s newly authorized robot, Italy’s $10 ...
– Vitestro, the pioneering autonomous blood drawing company, today announced that it has raised $22 million (€20 million) funding to accelerate commercialization of its innovative robotic blood ...
Vitestro, a Netherlands-based medical robotics company developing autonomous blood-drawing technology, has raised $70 million in an oversubscribed Series B financing round to accelerate development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results